Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients at least 18 years of age~* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)~* Rheumatoid factor and/or anti-CCP antibodies negative at screening~* A target skin psoriatic lesion and a PASI score of 1 or greater~Exclusion Criteria:~* Chest X-ray with evidence of ongoing infectious or malignant process~* Patients who ever received biologic immunomodulating agents including those targeting TNFα, IL-6 and IL-12/23 investigational or approved

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): secukinumab 300mg s.c. injection
- Group 2 (Type: ACTIVE_COMPARATOR): secukinumab 150 mg s.c. injection
- Group 3 (Type: PLACEBO_COMPARATOR): Placebo s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).